Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
28.03.2017 21:49:00

GENEWIZ To Launch Single-Cell RNA-Seq Services At AACR

Full Genomics Capabilities Including High Throughput Genomics, Sanger Sequencing, Synthetic Biology, and GLP-Compliant Services Also Showcased

SOUTH PLAINFIELD, New Jersey and WASHINGTON, March 28, 2017 /PRNewswire/ -- (AACR17, Booth #3431) – Leading global genomics service provider, GENEWIZ, will launch single-cell sequencing during the American Association for Cancer Research (AACR) Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C., April 1-5, 2017. Single-Cell RNA-Seq allows researchers to perform differential gene expression of thousands of cells at the individual level.

Photo - http://mma.prnewswire.com/media/483486/GENEWIZ_Single_Cell_RNA.jpg

Highlights:

  • Experts on-hand at AACR to discuss expanded next generation sequencing service offerings for cancer researchers including single-cell sequencing with the 10x Genomics® Chromium™, and whole genome sequencing with the Illumina HiSeq™ X Ten and the PacBio® Sequel.
  • Show-only discounts on GENEWIZ's complete service offering including: next generation and Sanger sequencing, gene synthesis, and GLP-compliant services.
  • Poster presentation in conjunction with Celsee Diagnostics:
    "Enrichment and Mutation Detection of Circulating Tumor Cells from Blood Samples"
    Liquid Biopsies 1: Circulating Tumor Cells
    Monday, April 3 -- 8 a.m. to Noon
    Poster Section 30 / Poster Board 10

"We are excited to introduce our new single-cell sequencing workflow at AACR as it will bring cancer researchers complete access to critical molecular information down to the cellular level," said Dr. Ginger Zhou, director of genomics and molecular genetics, GENEWIZ. "AACR brings together the best and the brightest in cancer research, making it an excellent opportunity for us to collaborate on new technologies and proprietery protocols that will help scientists advance their discoveries faster than ever before and ultimately transform cancer genomics."

About GENEWIZ
GENEWIZ is a global leader in genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in DNA sequencing, gene synthesis, molecular biology, high throughput sequencing, bioinformatics, and GLP regulatory-compliant services.

Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a global network of laboratories in Boston, MA; Washington, D.C. Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, Suzhou, and Tianjin, China; Takeley, United Kingdom; and Tokyo, Japan.  For more information, visit www.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, WeChat, and Weibo.

 

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!